Lancet Global Health: Paving the way for affordable and equitable liposomal amphotericin B access worldwide

Liposomal amphotericin B (LAmB) is a crucial, lifesaving medicine for treating many infectious diseases, but people in low- and middle-income countries (LMICs) lack access to affordable and quality-assured versions of the medicine. In this article in the Lancet Global Health, MSF Access Campaign’s Jessica Burry and co-authors identify the barriers to accessing LAmB and suggest how they could be addressed.